KLK3 and cancer: Metastatic castration-resistant prostate cancer (CRPC) is defined by consecutive rises in serum prostate-specific antigen (PSA) levels or/and progression of metastatic spread in the setting of castrate levels of testosterone due to the stage of cancer when it no longer completely responds to treatments that lower testosterone (Vlachostgrios et al., 2017).